| Literature DB >> 30023832 |
Mayank Joshi1, Angshuman Roy Choudhury1.
Abstract
The objective of pharmaceutical cocrystallization is to create crystalline analogues that have vastly different properties, such as solubility, melting point, stability, and bioavailability from that observed in the pure active pharmaceutical ingredients (APIs). Amoxapine is a benzoxazepine derivative and exhibits antidepressant properties. Amoxapine has very low solubility in water, so it was cocrystallized with natural acids in a 1:1 ratio in appropriate solvents by the solvent-drop grinding method. Single crystals of cocrystals were grown by the solvent evaporation method in water, ethanol, and methanol. Crystal structures of API salts were determined by single-crystal X-ray diffraction. Salts were characterized by Fourier transform infrared spectroscopy, differential scanning calorimetry, and powder X-ray diffraction. Solubility of salts was determined in water by the shake-flask method at 37 °C using UV-vis spectroscopy. Salts of amoxapine with different acids were successfully developed, and their crystal structure was determined. Enhanced solubility was found in the salts of amoxapine for pharmaceutical application in drug formulation.Entities:
Year: 2018 PMID: 30023832 PMCID: PMC6045396 DOI: 10.1021/acsomega.7b02023
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1Structure of amoxapine drug molecule.
pKa and ΔpKa Values of AMX and Coformers Used in This Study
| SI. no. | name | p | Δp | ratio of AMX and acid |
|---|---|---|---|---|
| 1 | amoxapine | 8.83 | ||
| 2 | 2.72 | 6.11 | 1:1 | |
| 3 | fumaric acid | 3.03 | 5.80 | 1:1 |
| 4 | 2.72 | 6.11 | 1:1 | |
| 5 | maleic acid | 3.05 | 5.78 | 1:1 |
| 6 | succinic acid | 3.55 | 5.28 | 1:1 |
| 7 | citric acid | 3.05 | 5.78 | 1:1 |
| 8 | malonic acid | 2.85 | 5.98 | 1:1 |
| 9 | 3.20 | 5.63 | 1:1 | |
| 10 | adipic acid | 4.43, 5.41 | 4.4, 3.42 | 1:1 |
Crystallographic Data of AMX Salts
| parameter | AMX/fumaric acid | AMX/maleic acid | AMX/succinic acid | AMX/malonic acid |
|---|---|---|---|---|
| empirical formula | 2(C17H17ClN3O)+, (C4H3O4)−, (C2HO2)−, 2(H2O) | (C17H17ClN3O)+, (C4H3O4)− | 2(C17H17ClN3O)+, (C4H4O4)2–, 5(H2O) | 2(C17H17ClN3O)+, (C3H2O4)2–, 2(H2O) |
| CCDC number | 1590199 | 1590200 | 1590201 | 1812331 |
| formula weight | 429.85 | 429.85 | 835.72 | 767.65 |
| crystal system | triclinic | monoclinic | monoclinic | monoclinic |
| space group | ||||
| 9.2238(2) | 20.5724(6) | 15.7210(2) | 21.3450(7) | |
| 12.4815(2) | 9.8586(3) | 19.4546(3) | 9.9547(3) | |
| 17.0725(3) | 9.7866(3) | 25.7568(4) | 17.4738(6) | |
| α (deg) | 86.2850(10) | 90 | 90 | 90 |
| β (deg) | 89.375(2) | 97.143(3) | 97.940(2) | 102.057(3) |
| γ (deg) | 82.224(2) | 90 | 90 | 90 |
| 1943.33(6) | 1969.46(10) | 7802.1(2) | 3631.0(2) | |
| 4 | 4 | 8 | 4 | |
| ρcalc (g/cm–3) | 1.469 | 1.450 | 1.423 | 1.404 |
| temperature (K) | 100.0(2) | 100.0(2) | 100.0(2) | 100.0(2) |
| μ/mm–1 | 0.237 | 0.234 | 0.236 | 0.241 |
| 2θmin,max (deg) | 5.062, 65.696 | 5.746, 65.678 | 5.078, 65.546 | 4.928, 65.604 |
| 896.0 | 896.0 | 3520.0 | 1608.0 | |
| –14, 14; –18, 17; –25, 25 | –30, 31; –14, 14; –14, 14 | –23, 23; –28, 29; –38, 38 | –32, 31; –14, 14; –26, 26 | |
| total no. of reflections | 43 941 | 43 349 | 183 373 | 67 443 |
| 0.0249 | 0.0525 | 0.0528 | 0.0546 | |
| no. of unique reflections | 13 758 | 7218 | 28 243 | 12 968 |
| 0.0419 | 0.0677 | 0.0699 | 0.0695 | |
| w | 0.1190 | 0.1989 | 0.2243 | 0.2009 |
| GooF on | 1.063 | 1.076 | 1.037 | 1.035 |
| Δρmax,min/e Å–3 | 0.61, −0.29 | 0.50, −0.37 | 1.19, −0.60 | 1.19, −0.51 |
Hydrogen Bond Geometry Parameters in Salts of AMX
| salts | interactions | D–H (Å) | H···A (Å) | D···A (Å) | D–H···A (deg) | symmetry code |
|---|---|---|---|---|---|---|
| AMX/fumaric acid (1:1) | N3–H3A···O6 | 0.91 | 1.81 | 2.703(1) | 166 | –1 + |
| N3–H3B···O5 | 0.91 | 1.93 | 2.821(1) | 165 | 1 – | |
| O4–H4A···O8 | 0.84 | 1.79 | 2.623(1) | 173 | 1 – | |
| N6–H6A···O7 | 0.91 | 1.82 | 2.717(1) | 167 | 1 – | |
| N6–H6B···O10 | 0.91 | 1.84 | 2.712(1) | 160 | 1 – | |
| O9–H9A···O8 | 0.85 | 1.98 | 2.817(1) | 166 | – | |
| O9–H9B···O6 | 0.85 | 1.95 | 2.804(1) | 179 | 1 – | |
| O10–H10A···O9 | 0.85 | 1.91 | 2.756(1) | 173 | 1 – | |
| O10–H10B···O7 | 0.85 | 1.91 | 2.747(1) | 171 | 1 – | |
| C14–H14A···O3 | 0.99 | 2.47 | 3.193(1) | 129 | ||
| C15–H15B···O1 | 0.99 | 2.58 | 3.142(1) | 116 | 1 – | |
| C16–H16B···O3 | 0.99 | 2.57 | 3.531(1) | 163 | – | |
| C31–H31B···O4 | 0.99 | 2.45 | 3.271(1) | 140 | – | |
| C32–H32B···Cl1 | 0.99 | 2.74 | 3.543(1) | 139 | ||
| C37–H37···O4 | 0.95 | 2.42 | 2.755(1) | 101 | ||
| C17–H17···π | 0.99 | 3.32 | 127 | |||
| AMX/maleic acid (1:1) | N3–H3A···O3 | 0.89 | 2.55 | 2.910(2) | 105 | – |
| N3–H3A···O3 | 0.89 | 1.89 | 2.767(2) | 167 | ||
| N3–H3B···O4 | 0.89 | 1.91 | 2.793(2) | 171 | ||
| O2–H5···O5 | 1.36(4) | 1.07(4) | 2.426(2) | 170 | ||
| C14–H14A···O2 | 0.97 | 2.58 | 3.188(2) | 121 | ||
| C15–H15A···O2 | 0.97 | 2.57 | 3.150(2) | 118 | ||
| C15–H15B···O5 | 0.97 | 2.57 | 3.165(2) | 120 | ||
| C19–H19···O3 | 0.93 | 2.37 | 3.269(2) | 162 | ||
| C16–H16B···Cl1 | 0.97 | 2.86 | 128 | |||
| C10–H10···π | 0.93 | 2.76 | 155 | |||
| AMX/succinic acid (1:1) | O00H–H00A···O10 | 0.85 | 1.93 | 2.771(3) | 171 | |
| N3–H3A···O5 | 0.89 | 1.86 | 2.734(3) | 165 | ||
| N3–H3B···O13 | 0.89 | 2.09 | 2.888(3) | 149 | ||
| N6–H6A···O14 | 0.89 | 1.84 | 2.701(3) | 162 | 2 – | |
| N6–H6B···O12 | 0.89 | 1.83 | 2.699(3) | 167 | 1 – | |
| N9–H9A···O18 | 0.89 | 1.82 | 2.681(3) | 162 | 1 – | |
| N9–H9B···O9 | 0.89 | 1.83 | 2.709(3) | 167 | 1 – | |
| N12–H12A···O8 | 0.89 | 1.86 | 2.732(3) | 165 | 1 – | |
| N12–H12B···O19 | 0.89 | 2.10 | 2.907(3) | 150 | 1 – | |
| O13–H13B···O12 | 0.85 | 1.99 | 2.749(2) | 148 | 1 + | |
| O14–H14C···O20 | 0.85 | 1.93 | 2.731(3) | 157 | 1 – | |
| O15–H15C···O7 | 0.85 | 1.98 | 2.816(3) | 167 | 1 – | |
| O16–H16C···O17 | 0.85 | 1.99 | 2.830(3) | 170 | 1 – | |
| O16–H16D···O6 | 0.85 | 1.97 | 2.818(3) | 172 | 1 – | |
| O17–H17C···O8 | 0.85 | 1.95 | 2.794(3) | 170 | 1 – | |
| O17–H17D···O10 | 0.85 | 2.02 | 2.853(3) | 167 | 1 – | |
| O19–H19A···O9 | 0.85 | 1.97 | 2.739(3) | 150 | 1 – | |
| O20–H20A···O11 | 0.85 | 1.93 | 2.779(3) | 177 | 1 – | |
| O20–H20B···O19 | 0.85 | 2.11 | 2.954(3) | 173 | 1 – | |
| O21–H21B···O11 | 0.85 | 2.04 | 2.860(3) | 163 | 1 – | |
| C17–H17A···N1 | 0.97 | 2.31 | 2.685(3) | 102 | 1 – | |
| C31–H31A···O4 | 0.97 | 2.57 | 3.377(3) | 141 | 1 – | |
| C34–H34A···O11 | 0.97 | 2.58 | 3.511(3) | 160 | 1 – | |
| C34–H34B···N4 | 0.97 | 2.35 | 2.704(3) | 101 | 1 – | |
| C51–H51A···O10 | 0.97 | 2.57 | 3.510(3) | 162 | 1 – | |
| C51–H51B···N7 | 0.97 | 2.34 | 2.692(3) | 101 | 1 – | |
| C65–H65A···O1 | 0.97 | 2.60 | 3.426(3) | 144 | ||
| C68–H68B···N10 | 0.97 | 2.31 | 2.688(3) | 102 | ||
| C49–H49B···π | 0.97 | 3.037 | 155 | |||
| C66–H66B···π | 0.97 | 2.904 | 152 | |||
| AMX/malonic acid (1:1) | N3–H3A···O4 | 0.89 | 2.50 | 3.109(3) | 126 | 1 – |
| N3–H3A···O6 | 0.89 | 2.20 | 2.883(3) | 133 | 1 – | |
| N3–H3B···O3 | 0.89 | 1.86 | 2.737(3) | 166 | ||
| N6–H6A···O5 | 0.89 | 1.85 | 2.717(3) | 163 | 1 – | |
| N6–H6A···O6 | 0.89 | 2.56 | 3.289(2) | 139 | 1 – | |
| N6–H6B···O3 | 0.89 | 2.49 | 3.122(3) | 128 | ||
| N6–H6B···O4 | 0.89 | 1.87 | 2.753(3) | 171 | ||
| O8–H8A···O9 | 0.85 | 2.33 | 2.897(3) | 125 | 1 – | |
| O8–H8B···O4 | 0.85 | 2.51 | 2.946(3) | 112 | 1 – | |
| O9–H9A···O6 | 0.85 | 2.00 | 2.837(3) | 169 | 1 – | |
| O9–H9B···O8 | 0.85 | 2.07 | 2.897(3) | 165 | 1 – | |
| O9–H9B···O7 | 0.85 | 1.93 | 2.737(11) | 158 | 1 – | |
| C10–H10···O9 | 0.93 | 2.56 | 3.486(3) | 176 | ||
| C12–H12···O2 | 0.93 | 2.53 | 3.238(3) | 133 | ||
| C32–H32A···O8 | 0.97 | 2.57 | 3.506(3) | 162 | 1 – | |
| C32–H32A···O7 | 0.97 | 2.55 | 3.400(11) | 146 | 1 – | |
| C32–H32B···O3 | 0.97 | 2.57 | 3.069(3) | 112 | ||
| C33–H33A···π | 0.97 | 3.175 | 145 | |||
| C34–H34A···π | 0.97 | 3.538 | 127 | |||
| C23–H23···π | 0.93 | 3.369 | 155 |
Figure 2(a) Asymmetric unit of AMX/fumaric acid cocrystal. (b) Intralayer interaction between drug molecules. (c) Layers of AMX and fumaric acid–water channel in crystal packing.
Figure 3(a) Asymmetric unit of AMX/maleic acid cocrystal. (b) Intralayer interaction of AMX along b axis. (c) Interlayer interactions along c axis and layers of AMX and maleic acid in crystal packing.
Figure 4(a) Asymmetric unit of AMX/succinic acid cocrystal. (b) Intralayer interaction of AMX molecules. (c) Layers of AMX and succinic acid–water channel in crystal packing.
Figure 5(a) Asymmetric unit of AMX/malonic acid salt. (b) Intralayer interaction of AMX. (c) Layers of AMX and malonic acid–water channel in crystal packing.
Melting Point and Melting Enthalpies of AMX and Its Salts
| name | melting point of API/conformer (°C) | melting point of salt with AMX (°C) | melting enthalpies (J/g) |
|---|---|---|---|
| amoxapine | 183.1 | 114.4 | |
| 173 | 147.2 | 83.0 | |
| fumaric acid | 287 | 127.2 | 13.9 |
| 206 | 147.1 | 45.1 | |
| maleic acid | 135 | 183.3 | 21.8 |
| succinic acid | 184 | 95.8 | 23.4 |
| citric acid | 153 | 209.5 | 442.6 |
| malonic acid | 135 | 162.3 | 11.6 |
| 131 | 173.0 | 60.4 | |
| adipic acid | 152 | 193.0 | 96.6 |
Solubility of AMX and Its Salts
| s. no. | compound | solubility (mg/mL) |
|---|---|---|
| 1 | AMX | 0.4 |
| 2 | AMX/ | 5.8 |
| 3 | AMX/fumaric acid | 10.7 |
| 4 | AMX/ | 6.1 |
| 5 | AMX/maleic acid | 2.7 |
| 6 | AMX/succinic acid | 4.7 |
| 7 | AMX/citric acid | 1.8 |
| 8 | AMX/malonic acid | 9.5 |
| 9 | AMX/ | 23.5 |
| 10 | AMX/adipic acid | 4.7 |
Figure 6Enhancement in solubility of salts of AMX.